283 related articles for article (PubMed ID: 20824828)
1. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
Erkens PM; Prins MH
Cochrane Database Syst Rev; 2010 Sep; (9):CD001100. PubMed ID: 20824828
[TBL] [Abstract][Full Text] [Related]
2. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Jones LE
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD001100. PubMed ID: 28182249
[TBL] [Abstract][Full Text] [Related]
3. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
van Dongen CJ; van den Belt AG; Prins MH; Lensing AW
Cochrane Database Syst Rev; 2004 Oct; (4):CD001100. PubMed ID: 15495007
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
5. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
[TBL] [Abstract][Full Text] [Related]
6. Home versus in-patient treatment for deep vein thrombosis.
Othieno R; Okpo E; Forster R
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD003076. PubMed ID: 29315455
[TBL] [Abstract][Full Text] [Related]
7. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Zorzela LM; Perini E
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007557. PubMed ID: 28431186
[TBL] [Abstract][Full Text] [Related]
8. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Perini E; Penholati RR; Carvalho MG
Cochrane Database Syst Rev; 2012 Sep; (9):CD007557. PubMed ID: 22972111
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children.
Pelland-Marcotte MC; Amiri N; Avila ML; Brandão LR
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD005982. PubMed ID: 32557627
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Vardi M; Zittan E; Bitterman H
Cochrane Database Syst Rev; 2009 Oct; (4):CD006771. PubMed ID: 19821386
[TBL] [Abstract][Full Text] [Related]
11. Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.
Costantino G; Ceriani E; Rusconi AM; Podda GM; Montano N; Duca P; Cattaneo M; Casazza G
PLoS One; 2012; 7(9):e44553. PubMed ID: 22984525
[TBL] [Abstract][Full Text] [Related]
12. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
Sandercock PA; Leong TS
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD000119. PubMed ID: 28374884
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Hakoum MB; Kahale LA; Tsolakian IG; Matar CF; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006649. PubMed ID: 29363105
[TBL] [Abstract][Full Text] [Related]
16. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Crawford F
Cochrane Database Syst Rev; 2012 Oct; 10():CD002001. PubMed ID: 23076894
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation.
Lin PT; Wang SH; Chi CC
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD009894. PubMed ID: 32302004
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation for perioperative thromboprophylaxis in people with cancer.
Matar CF; Kahale LA; Hakoum MB; Tsolakian IG; Etxeandia-Ikobaltzeta I; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009447. PubMed ID: 29993117
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
Magee KD; Sevcik W; Moher D; Rowe BH
Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
[TBL] [Abstract][Full Text] [Related]
20. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
